Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor

Scientific Reports

Volumn 4, Issue SREP03571, 2014, Pages

  Zhang, Ge ^a,b   Wang, Lei ^a,b   Cui, Honglian ^a   Wang, Xiaomin ^c   Zhang, Ganlin ^c   Ma, Juan ^a   Han, Huamin ^a   He, Wen ^d   Wang, Wei ^a   Zhao, Yunfeng ^a,b   Liu, Changzhen ^a   Sun, Meiyi ^e   Gao, Bin ^a,b  

^a INSTITUTE OF MICROBIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d HEBEI MEDICAL UNIVERSITY   (China)

^e Epigen Biotec Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANIMAL; ARTICLE; CELL CULTURE; FEMALE; HUMAN; IMMUNOLOGY; MELANOMA; MOUSE; PATHOLOGY; SCID MOUSE; T LYMPHOCYTE; TUMOR CELL CULTURE;

ANIMALS; CELLS, CULTURED; FEMALE; HUMANS; MELANOMA; MICE; MICE, SCID; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 84891786837     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03571     Document Type: Article

References (35)

1. Lesterhuis, W. J., Haanen, J. B. & Punt, C. J. Cancer immunotherapy-revisited. Nature reviews. Drug discovery 10, 591-600 (2011).
2. Flutter, B. & Gao, B.MHCclass I antigen presentation-recently trimmed and well presented. Cellular and Molecular Immunology 1, 22-30 (2004).
3. Imai, S. et al. Development of an antibody proteomics system using a phage antibody library for efficient screening of biomarker proteins. Biomaterials 32, 162-169 (2011).
4. Barrow, C. et al. Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage. Clinical Cancer Research 12, 764-771 (2006). (Pubitemid 43259856)
5. Kawakami, Y. et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proceedings of the National Academy of Sciences 91, 6458-6462 (1994).
6. Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546 (2009).
7. Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 12, 269-281 (2012).
8. Zhu, X. et al. COMBODY: one-domain antibody multimer with improved avidity. Immunology and Cell Biology 88, 667-675 (2010).
9. Klechevsky, E. et al. Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts. Cancer Research 68, 6360-6367 (2008).
10. Denkberg, G. et al. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proceedings of the National Academy of Sciences of the United States of America 99, 9421-9426 (2002). (Pubitemid 34764629)
11. Zhang, G. et al. Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody. Immunology and Cell Biology (2013).
12. Willemsen, R. A., Ronteltap, C., Chames, P., Debets, R. & Bolhuis, R. L. H. T cell retargeting with MHC class I-restricted antibodies: The CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production. Journal of Immunology 174, 7853-7858 (2005). (Pubitemid 40806294)
13. Jena, B., Dotti, G. & Cooper, L. J. N. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116, 1035-1044 (2010).
14. Kawakami, Y., Zakut, R., Topalian, S. L., Stotter, H. & Rosenberg, S. A. Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. Journal of immunology (Baltimore, Md.: 1950) 148, 638-643 (1992).
15. Hombach, A., Hombach, A. & Abken, H. Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer'domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target'activation and unintended initiation of an innate immune response. Gene therapy 17, 1206-1213 (2010).
16. Tiscornia, G., Singer, O. & Verma, I. M. Production and purification of lentiviral vectors. Nature protocols 1, 241-245 (2006).
17. Neri, S., Mariani, E., Meneghetti, A., Cattini, L. & Facchini, A. Calceinacetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clinical and diagnostic laboratory immunology 8, 1131-1135 (2001). (Pubitemid 33035744)
18. Rosenberg, S. A. & Dudley, M. E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Current Opinion in Immunology 21, 233-240 (2009).
19. Phan, G. Q. & Rosenberg, S. A. Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. Cancer control: journal of the Moffitt Cancer Center 20, 289-297 (2013).
20. Rosenberg, S. A. et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research 17, 4550-4557 (2011).
21. Wu, R. et al. Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma Current Status and Future Outlook. Cancer J. 18, 160-175 (2012).
22. van Loenen, M. M. et al. Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci U S A 107, 10972-10977 (2010).
23. Bendle, G. M. et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nature medicine 16, 565-570, 561p following 570 (2010).
24. Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Science Translational Medicine 3, 95ra73 (2011).
25. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia. New England Journal of Medicine 365, 725-733 (2011).
26. Leen, A. M., Rooney, C. M. & Foster, A. E. in Annual Review of Immunology Vol. 25, Annual Review of Immunology 243-265 (Annual Reviews, 2007).
27. Bakker, A. B. H. et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. Journal of Experimental Medicine 179, 1005-1009 (1994).
28. Dudley, M. E. et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298, 850-854 (2002). (Pubitemid 35231542)
29. Weijtens, M., Hart, E. & Bolhuis, R. Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production. Gene therapy 7, 35 (2000).
30. Gueorguieva, D. et al. Identification of single-domain, Bax-specific intrabodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis. Faseb J. 20, 2636-2638 (2006).
31. Kolkman, J. A. & Law, D. A. Nanobodies - from llamas to therapeutic proteins. Drug Discovery Today: Technologies 7, e139-e146 (2010).
32. Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. Journal of Clinical Oncology 24, e20-e22 (2006).
33. Bobisse, S. et al. Reprogramming T Lymphocytes for Melanoma Adoptive Immunotherapy by T-Cell Receptor Gene Transfer with Lentiviral Vectors. Cancer Research 69, 9385-9394 (2009).
34. Markley, J. C. & Sadelain, M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 115, 3508-3519 (2010).
35. Di Stasi, A. et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113, 6392-6402 (2009).